Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05297812 · ClinicalTrials.gov registry record

Alpha-1 Antitrypsin Disease Cohort: Longitudinal Biomarker Study of Disease

A clinical trial of Genetic Disease and Alpha-1 Antitrypsin Deficiency, sponsored by Columbia University.

Active
Registry status
286
Enrollment target
9
Study locations

NCT05297812 is a study of Genetic Disease and Alpha-1 Antitrypsin Deficiency that is active but no longer recruiting, run by Columbia University. The registered enrollment target is 286 participants, below the 2,552-participant average among 30 other Genetic Disease trials with a reported enrollment target (89% lower). The trial reports 9 study locations across 9 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05297812, a study of Genetic Disease and Alpha-1 Antitrypsin Deficiency, is active but no longer recruiting, sponsored by Columbia University.

ACTIVE NOT RECRUITING
Registry status
286 participants
Enrollment target
9
Study locations

Study Summary

Alpha-1 Anti-trypsin Deficiency (AATD) is a genetic disease with lung and liver disease presentations. The purpose of this study is to examine the density of the lung as measured by chest computed tomography (CT) and determine if existing emphysema predicts changes in the rate of subsequent emphysema or changes in CT, serum or plasma biomarkers of interest. The overarching goal is to develop biomarkers that can be used in interventional trials since lung function changes do not typically inform disease progression in AATD.

Conditions Studied

Genetic Disease Alpha-1 Antitrypsin Deficiency

Study Locations (9)

Alabama

  • University of Alabama at Birmingham - Birmingham

California

  • University of California - Los Angeles - Los Angeles

Colorado

  • National Jewish Health - Denver

Illinois

  • University of Chicago - Chicago

Massachusetts

  • Boston University - Boston

New York

  • Columbia University - New York

North Carolina

  • University of North Carolina - Chapel Hill

South Carolina

  • Medical University of South Carolina - Charleston

Trial Details

FieldValue
Enrollment Target 286 participants
Start Date 2022-03-23
Est. Completion 2027-01

Sponsor

Columbia University

958 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT05297812

The ClinicalTrials.gov registry entry for NCT05297812 describes a study currently listed as active not recruiting, categorized as an unspecified phase. The registered enrollment target is 286 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,552-participant average among 30 other Genetic Disease trials with a reported enrollment target (89% lower). The listed sponsor is Columbia University, which has 958 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Genetic Disease appearing as the primary indexed condition, and to 0 interventions.

NCT05297812 reports 9 study locations spanning 9 distinct geographic areas - top geographies include Alabama, California, Colorado.

Frequently Asked Questions

What is clinical trial NCT05297812 about?

NCT05297812 is a clinical study titled "Alpha-1 Antitrypsin Disease Cohort: Longitudinal Biomarker Study of Disease". Alpha-1 Anti-trypsin Deficiency (AATD) is a genetic disease with lung and liver disease presentations. The purpose of this study is to examine the density of the lung as measured by chest computed tomography (CT) and determine if existing emphysema predicts changes in the rate of subsequent emphysem...

What is the current status of trial NCT05297812?

This trial is currently active not recruiting. The enrollment target is 286 participants. The study started on 2022-03-23. Estimated completion is 2027-01.

What conditions does trial NCT05297812 study?

This clinical trial studies the following conditions: Genetic Disease, Alpha-1 Antitrypsin Deficiency.

Who is sponsoring clinical trial NCT05297812?

This trial is sponsored by Columbia University, which has 958 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05297812 being conducted?

This trial has 9 study locations across Alabama, California, Colorado, Illinois, Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Genetic Disease

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Genetic Disease

All registered trials for this condition

Alpha-1 Antitrypsin Deficiency

All registered trials for this condition

Alabama

All trials with a study site in Alabama

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.